| Customization: | Available |
|---|---|
| Type: | Gastrointestinal Drug Omeprazole Sodium |
| Material: | Liquid |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Indications:
Omeprazole for intravenous use is indicated as an alternative to oral therapy for the following indications i.e.
• Treatment of duodenal ulcers
• Prevention of relapse of duodenal ulcers
• Treatment of gastric ulcers
• Prevention of relapse of gastric ulcers
• In combination with appropriate antibiotics, Helicobacter pylori (H. pylori) eradication in peptic ulcer disease
• Treatment of NSAID-associated gastric and duodenal ulcers
• Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk
• Treatment of reflux oesophagitis
• Long-term management of patients with healed reflux oesophagitis
• Treatment of symptomatic gastro-oesophageal reflux disease
• Treatment of Zollinger-Ellison syndrome
Dosage and Administration:
In patients where the use of oral medicinal products is inappropriate, Omeprazole IV 40 mg once daily is recommended. In patients with Zollinger-Ellison Syndrome the recommended initial dose of Omeprazole given intravenously is 60 mg daily. Higher daily doses may be required and the dose should be adjusted individually. When doses exceed 60 mg daily, the dose should be divided and given twice daily.
Omeprazole is to be administered in an intravenous infusion for 20-30 minutes.
Contra-indications:
Hypersensitivity to omeprazole, substituted benzimidazoles or to any of the excipients.
Omeprazole like other proton pump inhibitors (PPIs) should not be used concomitantly with nelfinavir.
Drug interactions:
Active substances with pH dependent absorption:
Nelfinavir, Atazanavir,Digoxin,Clopidogrel
Other active substances:
The absorption of posaconazole, erlotinib, ketoconazol and itraconazol is significantly reduced and thus clinical efficacy may be impaired. For posaconazol and erlotinib concomitant use should be avoided.
Active substances metabolised by CYP2C19:
Omeprazole is a moderate inhibitor of CYP2C19, the major omeprazole metabolising enzyme. Thus, the metabolism of concomitant active substances also metabolised by CYP2C19, may be decreased and the systemic exposure to these substances increased. Examples of such medicinal products are R-warfarin and other vitamin K antagonists, cilostazol and phenytoin.
Unknown mechanism: Saquinavir, Tacrolimus
Effects of other active substances on the pharmacokinetics of omeprazole:
Inhibitors of CYP2C19 and/or CYP3A4
Inducers of CYP2C19 and/or CYP3A4
Storage instructions:
Do not store above 25°C. Keep vials in the outer carton in order to protect from light.
){kind=link}